Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for KERX
-0.14 (-2.37%)
Real-time:   1:41PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.74 - 5.98
52 week 2.80 - 10.80
Open 5.93
Vol / Avg. 538,200.00/1.40M
Mkt cap 621.10M
P/E     -
Div/yield     -
EPS -1.30
Shares 105.82M
Beta 4.04
Inst. own 65%
Aug 3, 2016
Q2 2016 Keryx Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 15, 2016
Keryx Biopharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
May 25, 2016
Keryx Biopharmaceuticals Inc Annual Shareholders Meeting
Apr 28, 2016
Q1 2016 Keryx Biopharmaceuticals Inc Earnings Release
Apr 28, 2016
Q1 2016 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
Mar 29, 2016
Keryx Biopharmaceuticals Inc Phase 3 IDA/CKD Results Call - Webcast
Mar 7, 2016
Keryx Biopharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -600.21% -900.18%
Operating margin -342.81% -811.90%
EBITD margin - -807.54%
Return on average assets -67.31% -67.98%
Return on average equity -241.04% -153.53%
Employees 184 -
CDP Score - -


750 Lexington Ave
NEW YORK, NY 10022-1200
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Gregory Paul Madison Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Scott A. Holmes Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Age: 41
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
John F. Neylan Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Lauren Fischer Director
Bio & Compensation  - Reuters
John P Butler Independent Director
Age: 50
Bio & Compensation  - Reuters
Kevin J. Cameron Independent Director
Age: 46
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters